Research > ETFs > ETF / ETP Commentary > 

Private Credit Offers Viable Yield Path as Rates Stay Elevated

  • Related Symbols
  • PCR
New U.S. Federal Reserve chair Kevin Warsh certainly has his work cut out for him. An overheated economy that once expected rate cuts is now facing the possibility of rate hikes, pushing bond-reliant fixed income investors to find alternate paths to yield. Private credit could offer that solution.Key Takeaways: Federal Reserve policy uncertainty is pushing investors from traditional bonds toward private credit to protect their yield from potential rate hikes. Private credit uses floating-rate benchmarks like SOFR that adjust upward with rising interest rates. It also offers a substantial yield premium over traditional corporate bonds. The Simplify VettaFi Private Credit Strategy ETF (PCR) opens up this institutional market to everyday investors. It provides a 10.87% monthly distribution rate within a liquid ETF wrapper. See more: The Case for Active Management in the Private Credit MarketStructural Advantages of Private CreditPrivate credit offers certain structural advantages that investors can’t get from traditional bonds. Firstly, bonds are highly sensitive to duration risk. This leaves investors vulnerable if the Fed decides that the hot economy warrants a hawkish pivot. To mitigate this rate risk, structural insulation requires a shift toward floating-rate alternatives. Private credit loans are typically tied to floating rate benchmarks like the Secured Overnight Financing Rate (SOFR). As such, their coupons reset higher alongside rising interest rates. This makes them ideal in a rising-rate environment to hedge against inflationary pressures. Additionally, private credit offers a substantial yield premium compared to traditional corporate bonds. This premium is a result of private credit transactions requiring complex structuring, extensive fundamental underwriting, and direct relationships with corporate borrowers. In a higher-for-longer rate environment such as now, capturing this premium can preserve purchasing power and yield from the effects of persistent inflation.PCR: The Access PointHistorically, private credit was only available to institutional investors. Also, it required investors to lock up capital in closed-end, draw-down private funds. The advent of the exchange-traded fund (ETF) essentially changed the game for access to private credit. For income-focused investors looking to pivot away from traditional bonds and seek additional avenues for yield, the Simplify VettaFi Private Credit Strategy ETF (PCR) delivers an optimized access point into private credit. PCR invests the majority of its net assets in securities from the VettaFi Private Credit Index. The fund deploys a multi-manager strategy that captures high-yielding corporate direct loans, specialty finance, and structured credit within the liquid wrapper of an ETF. PCR offers a monthly distribution rate of 10.87% (as of April 30, 2026). By combining the premium yield of private lending markets with intraday dealing liquidity, PCR allows advisors to actively defend client portfolios against today’s challenging macroeconomic environment. For more news, information, and analysis, visit the Institutional Income Strategies Content Hub. VettaFi LLC (“VettaFi”) is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.